Literature DB >> 33630181

Cannabis and Migraine: It's Complicated.

Laszlo L Mechtler1, Fran M Gengo2, Vincent H Bargnes3.   

Abstract

PURPOSE OF REVIEW: The use of cannabis for the treatment of migraine has become an area of interest with the legalization of medical cannabis in the USA. Understanding the mechanisms of cannabinoids, available studies, and best clinical recommendations is crucial for headache providers to best serve patients. RECENT
FINDINGS: Patients utilizing medical cannabis for migraine have reported improvement in migraine profile and common comorbidities. Reduction in prescription medication is also common, especially opioids. Side effects exist, with the majority being mild. Not enough data is available for specific dose recommendations, but THC and CBD appear to mediate these observed effects. The purpose of this article is twofold: review the limited research surrounding cannabis for migraine disease and reflect on clinical management experiences to provide recommendations that best capture the potential use of cannabis for migraine.

Entities:  

Keywords:  Cannabis; Headache; Marijuana; Medical cannabis; Medical marijuana; Migraine

Year:  2021        PMID: 33630181     DOI: 10.1007/s11916-020-00931-2

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  40 in total

1.  Fremanezumab for the Preventive Treatment of Chronic Migraine.

Authors:  Stephen D Silberstein; David W Dodick; Marcelo E Bigal; Paul P Yeung; Peter J Goadsby; Tricia Blankenbiller; Melissa Grozinski-Wolff; Ronghua Yang; Yuju Ma; Ernesto Aycardi
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

2.  Ubrogepant for the Treatment of Migraine.

Authors:  David W Dodick; Richard B Lipton; Jessica Ailani; Kaifeng Lu; Michelle Finnegan; Joel M Trugman; Armin Szegedi
Journal:  N Engl J Med       Date:  2019-12-05       Impact factor: 91.245

Review 3.  Chemical constituents of marijuana: the complex mixture of natural cannabinoids.

Authors:  Mahmoud A Elsohly; Desmond Slade
Journal:  Life Sci       Date:  2005-09-30       Impact factor: 5.037

4.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

5.  An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity.

Authors:  S Ben-Shabat; E Fride; T Sheskin; T Tamiri; M H Rhee; Z Vogel; T Bisogno; L De Petrocellis; V Di Marzo; R Mechoulam
Journal:  Eur J Pharmacol       Date:  1998-07-17       Impact factor: 4.432

Review 6.  Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain.

Authors:  Rodrigo Noseda; Rami Burstein
Journal:  Pain       Date:  2013-07-25       Impact factor: 6.961

7.  Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists.

Authors:  Dan Levy; Moshe Jakubowski; Rami Burstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

8.  Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference.

Authors:  Steffen Naegel; Mark Obermann
Journal:  Neuropsychiatr Dis Treat       Date:  2010-02-03       Impact factor: 2.570

9.  Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations.

Authors:  Sang Won Jung; Art E Cho; Wookyung Yu
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

10.  The heterogeneity and complexity of Cannabis extracts as antitumor agents.

Authors:  Liran Baram; Ella Peled; Paula Berman; Ben Yellin; Elazar Besser; Maya Benami; Igal Louria-Hayon; Gil M Lewitus; David Meiri
Journal:  Oncotarget       Date:  2019-06-25
View more
  1 in total

1.  Cannabinoids-Perspectives for Individual Treatment in Selected Patients: Analysis of the Case Series.

Authors:  Michał Graczyk; Agata Anna Lewandowska; Piotr Melnyczok; Adam Zgliński; Małgorzata Łukowicz
Journal:  Biomedicines       Date:  2022-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.